Gilead Keeps Climbing Out Of Veklury’s Shadow As Core Business Growth Strengthens
Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.
Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.